Employers expect healthcare costs to rise by a median of 9% in 2026, according to a survey by the Business Group on Health. Pharmacy expenses are a key driver.| MedCity News
Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s room for many MASH drugs with the treatment landscape expected to shape up to include combinations of therapies bringing different approaches to this fatty liver disease.| MedCity News
When transportation is integrated into the care continuum, everyone benefits: costs go down, appointments stay on track and beneficiaries receive the consistent care they deserve. This transformation isn’t just about speed; it’s about making every ride count.| MedCity News
By creating payment experiences that feel less like a burden and more like the seamless, convenient, flexible transactions patients experience elsewhere, we can significantly improve both patient satisfaction and financial performance.| MedCity News